By Professor David Goldstein

Journal articles

Yang JL; Gupta RD; Goldstein D; Crowe PJ, 2017, 'Significance of phosphorylated epidermal growth factor receptor and its signal transducers in human soft tissue sarcoma', International Journal of Molecular Sciences, 18, pp. 1159, http://dx.doi.org/10.3390/ijms18061159

Sjoquist KM; Pavlakis N; Martin AJ; Tsobanis E; Yip S; Bang Y-J; Alcindor T; O'Callaghan CJ; Shitara K; Bekaii-Saab TS; Grothey A; Chen L-T; Simes J; Zalcberg JR; Goldstein D, 2017, 'Integrate II: A randomised phase 3 double-blind placebo-controlled study of regorafenib in refractory advanced gastro-oesophageal cancer (AGOC)—An international study organized by the Australasian Gastrointestinal Trials Group (AGITG).', Journal of Clinical Oncology, 35, pp. TPS4136 - TPS4136, http://dx.doi.org/10.1200/jco.2017.35.15_suppl.tps4136

Schernberg A; Vernerey D; Goldstein D; Van Laethem JL; Glimelius B; Van Houtte P; Bonnetain F; Louvet C; Hammel P; Huguet F, 2017, 'Neutrophil count and efficacy of chemoradiation in patients with locally advanced unresectable pancreatic carcinoma: An ancillary study of in the LAP 07 trial.', Journal of Clinical Oncology, 35, pp. 4120 - 4120, http://dx.doi.org/10.1200/jco.2017.35.15_suppl.4120

Goldstein D; Von Hoff DD; Chiorean EG; Reni M; Tabernero J; Ramanathan RK; Aly A; Botteman M; Wilkersen J; Margunato-Debay S; Lu B; Louis CU; Renschler MF; McGovern DMT; Lee CK, 2017, 'Nomogram for predicting overall survival (OS) in patients (pts) treated with nab-paclitaxel (nab-P) plus gemcitabine (Gem) or Gem alone for metastatic pancreatic cancer (MPC).', Journal of Clinical Oncology, 35, pp. 4109 - 4109, http://dx.doi.org/10.1200/jco.2017.35.15_suppl.4109

Lee B; Cohen J; Lipton LR; Tie J; Javed AA; Li L; Goldstein D; Cooray P; Nagrial A; Burge ME; Tebbutt NC; Nikfarjam M; Harris M; O'Broin-Lennon AM; Wolfgang CL; Tomasetti C; Papadopoulos N; Kinzler KW; Vogelstein B; Gibbs P, 2017, 'Potential role of circulating tumor DNA (ctDNA) in the early diagnosis and post-operative management of localised pancreatic cancer.', Journal of Clinical Oncology, 35, pp. 4101 - 4101, http://dx.doi.org/10.1200/jco.2017.35.15_suppl.4101

Tie J; Cohen J; Wang Y; Li L; Kinde I; Elsaleh H; Wong R; Kosmider S; Yip D; Lee M; Tran B; Burge ME; Goldstein D; Singh MS; Diaz LA; Tomasetti C; Papadopoulos N; Kinzler KW; Vogelstein B; Gibbs P, 2017, 'The potential of circulating tumor DNA (ctDNA) to guide adjuvant chemotherapy decision making in locally advanced rectal cancer (LARC).', Journal of Clinical Oncology, 35, pp. 3521 - 3521, http://dx.doi.org/10.1200/jco.2017.35.15_suppl.3521

McNamara MG; Bridgewater J; Lopes A; Wasan H; Malka D; Jensen LH; Okusaka T; Knox JJ; Wagner D; Cunningham D; Shannon J; Goldstein D; Moehler M; Bekaii-Saab T; Valle JW, 2017, 'Systemic therapy in younger and elderly patients with advanced biliary cancer: Sub-analysis of ABC-02 and twelve other prospective trials', BMC Cancer, 17, pp. 262, http://dx.doi.org/10.1186/s12885-017-3266-9

Sandler CX; Goldstein D; Horsfield S; Bennett BK; Friedlander M; Bastick PA; Lewis CR; segelov E; Boyle FM; Chin MT; webber K; Barry BK; Lloyd AR, 2017, 'Randomized evaluation of cognitive-behavioral therapy and graded exercise therapy for post-cancer fatigue.', Journal of Pain and Symptom Management, http://dx.doi.org/10.1016/j.jpainsymman.2017.03.015

Janda M; Neale RE; Klein K; O'Connell DL; Gooden H; Goldstein D; Merrett ND; Wyld DK; Rowlands IJ; Beesley VL, 2017, 'Anxiety, depression and quality of life in people with pancreatic cancer and their carers', Pancreatology, 17, pp. 321 - 327, http://dx.doi.org/10.1016/j.pan.2017.01.008

Lees JG; Makker PGS; Tonkin RS; Abdulla M; Park SB; Goldstein D; Moalem-Taylor G, 2017, 'Immune-mediated processes implicated in chemotherapy-induced peripheral neuropathy', European Journal of Cancer, 73, pp. 22 - 29, http://dx.doi.org/10.1016/j.ejca.2016.12.006

Goldstein D; Lemech C; Valle J, 2017, 'New molecular and immunotherapeutic approaches in biliary cancer', ESMO Open, 2, pp. e000152, http://dx.doi.org/10.1136/esmoopen-2016-000152

Watts KJ; Meiser B; Zilliacus E; Kaur R; Taouk M; Girgis A; Butow P; Goldstein D; Hale S; Perry A; Aranda SK; Kissane DW, 2017, 'Communicating with patients from minority backgrounds: Individual challenges experienced by oncology health professionals', European Journal of Oncology Nursing, 26, pp. 83 - 90, http://dx.doi.org/10.1016/j.ejon.2016.12.001

Tang M; Chen J; Goldstein D; Links M; Lord S; Marschner I; Simes J; Lee CK, 2017, 'Correlation of phase 2 trials (Ph2t) results with outcomes of phase 3 trials (Ph3t) of investigational agents (IA) in locally advanced and metastatic pancreas cancer (LAMPC).', JOURNAL OF CLINICAL ONCOLOGY, 35, http://dx.doi.org/10.1200/JCO.2017.35.4_suppl.227

Chan DL; Sjoquist KM; Goldstein D; Price TJ; Martin AJ; Bang YJ; Kang YK; Pavlakis N, 2017, 'The effect of anti-angiogenic agents on overall survival in metastatic oesophago-gastric cancer: A systematic review and meta-analysis', PLoS ONE, 12, pp. e0172307, http://dx.doi.org/10.1371/journal.pone.0172307

Atlin CR; Johnson-Obaseki S; Chung J; Bloom JA; Jaakkimainen L; Waldron J; Goldstein D, 2017, 'Assessing the need for an educational intervention for primary care practitioners on HPV-related oropharyngeal cancer', University of Toronto Medical Journal, 94, pp. 17 - 21

Makker PGS; Duffy SS; Lees JG; Perera CJ; Tonkin RS; Butovsky O; Park SB; Goldstein D; Moalem-Taylor G, 2017, 'Characterisation of immune and neuroinflammatory changes associated with chemotherapy-induced peripheral neuropathy', PLoS ONE, 12, pp. e0170814, http://dx.doi.org/10.1371/journal.pone.0170814

Sharbeen G; Youkhana J; Mawson A; McCarroll J; Nunez A; Biankin A; Johns A; Goldstein D; Phillips P, 2017, 'MutY-Homolog (MYH) inhibition reduces pancreatic cancer cell growth and increases chemosensitivity', Oncotarget, 8, pp. 9216 - 9229, http://dx.doi.org/10.18632/oncotarget.13985

Ritchie GE; Fernando M; Goldstein D, 2017, 'Rituximab to treat gemcitabine-induced hemolytic–uremic syndrome (HUS) in pancreatic adenocarcinoma: a case series and literature review', Cancer Chemotherapy and Pharmacology, 79, http://dx.doi.org/10.1007/s00280-016-3123-6

Pothula SP; Xu Z; Goldstein D; Merrett N; Pirola RC; Wilson JS; Apte MV, 2017, 'Targeting the HGF/c-MET pathway: Stromal remodelling in pancreatic cancer', Oncotarget, 8, pp. 76722 - 76739, http://dx.doi.org/10.18632/oncotarget.20822

Tang M; Goldstein D, 2017, 'The role of chemotherapy in gastric cancer-related microangiopathic haemolytic anaemia', Journal of Gastrointestinal Oncology, 8, pp. E10 - E15, http://dx.doi.org/10.21037/jgo.2016.11.14

Kunzmann V; Ramanathan RK; Goldstein D; Liu H; Ferrara S; Lu B; Renschler MF; Von Hoff DD, 2017, 'Tumor reduction in primary andmetastatic pancreatic cancer lesions with nab-paclitaxel and gemcitabine: An exploratory analysis from a phase 3 study', Pancreas, 46, pp. 203 - 208, http://dx.doi.org/10.1097/MPA.0000000000000742

Schernberg A; Vernerey D; Goldstein D; Van Laethem JL; Van Houtte PJ; Bonnetain F; Glimelius B; Louvet C; Hammel P; Huguet F, 2017, 'Neutrophils Predicting Tumor Local Control After Chemoradiation Therapy in Locally Advanced Pancreatic Carcinoma in the LAP 07 Trial', International Journal of Radiation Oncology*Biology*Physics, 99, pp. S88 - S89, http://dx.doi.org/10.1016/j.ijrobp.2017.06.213

Burmeister EA; O’Connell DL; Jordan SJ; Goldstein D; Merrett N; Wyld DK; Beesley VL; Gooden HM; Janda M; Neale RE, 2016, 'Factors associated with quality of care for patients with pancreatic cancer in Australia', Medical Journal of Australia, 205, pp. 459 - 465, http://dx.doi.org/10.5694/mja16.00567

Yang JL; Lim HJ; Wang X; Crowe PJ; Goldstein D, 2016, 'Targeting the PI3K/PTEN/AKT/mTOR Pathway in Treatment of Sarcoma Cell Lines', Anticancer research, 36, pp. 5765 - 5772, http://dx.doi.org/10.21873/anticanres.11160

Kandula T; Park SB; Cohn RJ; Krishnan AV; Farrar MA; Goldstein D, 2016, 'Pediatric chemotherapy induced peripheral neuropathy: A systematic review of current knowledge', Cancer Treatment Reviews, 50, pp. 118 - 128, http://dx.doi.org/10.1016/j.ctrv.2016.09.005

Vickers MM; Lee C; Tu D; Wheatley-Price P; Parulekar W; Brundage MD; Moore MJ; Au H; O'Callaghan CJ; Jonker DJ; Ringash J; Goldstein D, 2016, 'Significance of baseline and change in quality of life scores in predicting clinical outcomes in an international phase III trial of advanced pancreatic cancer: NCIC CTG PA.3', Pancreatology, 16, pp. 1106 - 1112, http://dx.doi.org/10.1016/j.pan.2016.08.013

Chiorean EG; Von Hoff DD; Tabernero J; El-Maraghi R; Ma WW; Reni M; Harris M; Whorf R; Liu H; Li JS; Manax V; Romano A; Lu B; Goldstein D, 2016, 'Second-line therapy after nab-paclitaxel plus gemcitabine or after gemcitabine for patients with metastatic pancreatic cancer (vol 115, pg 188, 2016)', BRITISH JOURNAL OF CANCER, 115, pp. E13 - U13, http://dx.doi.org/10.1038/bjc.2016.306

Huguet F; Goldstein D; Hammel P, 2016, 'Radiation therapy deviations in trial of locally advanced pancreatic cancer: In Reply', JAMA - Journal of the American Medical Association, 316, pp. 1409 - 1410, http://dx.doi.org/10.1001/jama.2016.9781

de Souza P; Chua W; Clarke S; Goldstein D; Lee C, 2016, 'Inflammatory Markers Have a Role in Renal Cell Carcinoma Prognosis', European Urology Focus, 2, pp. 341 - 342, http://dx.doi.org/10.1016/j.euf.2016.04.007

Gormly KL; Coscia C; Wells T; Tebbutt N; Harvey JA; Wilson K; Schmoll HJ; Price T; Hruby G; Jeffery M; Karapetis C; Ng W; Singhal N; Burge M; Lynch R; Briscoe K; Begbie S; Gill S; Sebesan S; Goldstein D; Ng S; Asghari R; Blum R; Walpole E; Byard I, 2016, 'MRI rectal cancer in Australia and New Zealand: An audit from the PETACC-6 trial', Journal of Medical Imaging and Radiation Oncology, 60, pp. 607 - 615, http://dx.doi.org/10.1111/1754-9485.12493

Wang X; Goldstein D; Crowe PJ; Yang JL, 2016, 'Next-generation EGFR/HER tyrosine kinase inhibitors for the treatment of patients with non-small-cell lung cancer harboring EGFR mutations: A review of the evidence', OncoTargets and Therapy, 9, pp. 5461 - 5473, http://dx.doi.org/10.2147/OTT.S94745

Burmeister EA; Waterhouse M; Jordan SJ; O'Connell DL; Merrett ND; Goldstein D; Wyld D; Beesley V; Gooden H; Janda M; Neale RE, 2016, 'Determinants of survival and attempted resection in patients with non-metastatic pancreatic cancer: An Australian population-based study', Pancreatology, 16, pp. 873 - 881, http://dx.doi.org/10.1016/j.pan.2016.06.010

Pavlakis N; Sjoquist KM; Martin AJ; Tsobanis E; Yip S; Kang YK; Bang YJ; Alcindor T; O'Callaghan CJ; Burnell MJ; Tebbutt NC; Rha SY; Lee J; Cho JY; Lipton LR; Wong M; Strickland A; Kim JW; Zalcberg JR; Simes J; Goldstein D, 2016, 'Regorafenib for the treatment of advanced gastric cancer (INTEGRATE): A multinational placebo-controlled phase II Trial', Journal of Clinical Oncology, 34, pp. 2728 - 2735, http://dx.doi.org/10.1200/JCO.2015.65.1901

Waterhouse MA; Burmeister EA; O’Connell DL; Ballard EL; Jordan SJ; Merrett ND; Goldstein D; Wyld D; Janda M; Beesley VL; Payne ME; Gooden HM; Neale RE, 2016, 'Determinants of Outcomes Following Resection for Pancreatic Cancer—a Population-Based Study', Journal of Gastrointestinal Surgery, 20, pp. 1471 - 1481, http://dx.doi.org/10.1007/s11605-016-3157-4

Beesley V; Wockner L; O'Rourke P; Janda M; Merrett H; Goldstein D; Gooden H; Merrett N; O'Connell D; Rowlands I; Wyld D; Neale R, 2016, 'Erratum to: Risk factors for current and future unmet supportive care needs of people with pancreatic cancer. A longitudinal study (Support Care Cancer, 10.1007/s00520-016-3212-4)', Supportive Care in Cancer, 24, pp. 3601 - 3602, http://dx.doi.org/10.1007/s00520-016-3251-x

Beesley VL; Wockner LF; O’Rourke P; Janda M; Goldstein D; Gooden H; Merrett ND; O’Connell DL; Rowlands IJ; Wyld DK; Neale RE, 2016, 'Risk factors for current and future unmet supportive care needs of people with pancreatic cancer. A longitudinal study', Supportive Care in Cancer, 24, pp. 3589 - 3599, http://dx.doi.org/10.1007/s00520-016-3212-4

Ferraro D; Goldstein D; O'Connell RL; Zalcberg JR; Sjoquist KM; Tebbutt NC; Grimison P; McLachlan S; Lipton LL; Vasey P; Gebski VJ; Aiken C; Cronk M; Ng S; Karapetis CS; Shannon J; Do V; Marschner I; Friedlander M; Gurney H; Simes J; Hague W; O’Connell R; Gorzeman M; Pike R; Miranda K; Waring P; Lau D; Fox S; Liu Y; Wood T; Cocks C; Simmons K; McCourt J; Jefford M; Hobinchet A; Mirco B; Sagong J; Dudukovic S; Aghmesheh M; Parker S; Segelov E; Ratnayake L; Ranieri N; Varma S; Page J; Heyer E; Abdi E; Chorlton C; Wilkinson L; Marshall I, 2016, 'TACTIC: a multicentre, open-label, single-arm phase II trial of panitumumab, cisplatin, and gemcitabine in biliary tract cancer', Cancer Chemotherapy and Pharmacology, 78, pp. 361 - 367, http://dx.doi.org/10.1007/s00280-016-3089-4

Vernerey D; Huguet F; Vienot A; Goldstein D; Paget-Bailly S; Van Laethem JL; Glimelius B; Artru P; Moore MJ; André T; Mineur L; Chibaudel B; Benetkiewicz M; Louvet C; Hammel P; Bonnetain F, 2016, 'Prognostic nomogram and score to predict overall survival in locally advanced untreated pancreatic cancer (PROLAP)', British Journal of Cancer, 115, pp. 281 - 289, http://dx.doi.org/10.1038/bjc.2016.212

Chiorean EG; Von Hoff DD; Tabernero J; El-Maraghi R; Ma WW; Reni M; Harris M; Whorf R; Liu H; Li JS; Manax V; Romano A; Lu B; Goldstein D, 2016, 'Second-line therapy after nab-paclitaxel plus gemcitabine or after gemcitabine for patients with metastatic pancreatic cancer', British Journal of Cancer, 115, pp. 188 - 194, http://dx.doi.org/10.1038/bjc.2016.185

Gandy RC; Barbour AP; Samra J; Nikfarjam M; Haghighi K; Kench JG; Saxena P; Goldstein D, 2016, 'Refining the care of patients with pancreatic cancer: The AGITG Pancreatic Cancer Workshop consensus', Medical Journal of Australia, 204, pp. 419 - 422.e1, http://dx.doi.org/10.5694/mja16.00061

Gandy RC; Barbour AP; Samra J; Nikfarjam M; Haghighi K; Kench JG; Saxena P; Goldstein D, 2016, 'Refining the care of patients with pancreatic cancer: the AGITG Pancreatic Cancer Workshop consensus', MEDICAL JOURNAL OF AUSTRALIA, 204, pp. 419 - +, http://dx.doi.org/10.5694/mja16.00061

Scheithauer W; Ramanathan RK; Moore M; Macarulla T; Goldstein D; Hammel P; Kunzmann V; Liu H; McGovern D; Romano A; Von Hoff DD, 2016, 'Dose modification and efficacy of nab-paclitaxel plus gemcitabine vs. gemcitabine for patients with metastatic pancreatic cancer: Phase III MPACT trial', Journal of Gastrointestinal Oncology, 7, pp. 469 - 478, http://dx.doi.org/10.21037/jgo.2016.01.03

Shaw JM; Shepherd HL; Durcinoska I; Butow PN; Liauw W; Goldstein D; Young JM, 2016, 'It’s all good on the surface: care coordination experiences of migrant cancer patients in Australia', Supportive Care in Cancer, 24, pp. 2403 - 2410, http://dx.doi.org/10.1007/s00520-015-3043-8

Burmeister EA; Jordan SJ; O’Connell DL; Beesley VL; Goldstein D; Gooden HM; Janda M; Merrett ND; Wyld D; Neale RE; Cosman PH; Bullen A; Burge M; Eastgate M; Powell J; Deuble M; Pryor D; Whelan J; Algie L; Gupta S; Lynch SV; Burmeister BH; Slater K; Fletcher D; Van Hazel G; Raftopoulos S; Spry N; Agar M; Brecciaroli F; Caird S; Cameron D; Chan P; Chantrill L; Christie D; Chua YJ; Croese J; Cronk M; Gani J; Grimison P; Hruby G; Jefford M; Samra JS; Wysocki AP, 2016, 'Using a Delphi process to determine optimal care for patients with pancreatic cancer', Asia-Pacific Journal of Clinical Oncology, 12, pp. 105 - 114, http://dx.doi.org/10.1111/ajco.12450

Barbour A; O'Rourke N; Chan H; Chua YJ; Kench J; Hicks RJ; Samra JS; Pavlakis N; Haghighi KS; Yip S; Donoghoe M; Friend C; Burge ME; Fawcett J; Harris M; Aghmesheh M; Joubert WL; Gebski V; Simes J; Goldstein D, 2016, 'Initial survival outcomes for the AGITG GAP study - a phase II study of perioperative nab-paclitaxel and gemcitabine for resectable pancreatic ductal adenocarcinoma (PDAC)', JOURNAL OF CLINICAL ONCOLOGY, 34, http://dx.doi.org/10.1200/JCO.2016.34.15_suppl.4105

Hammel P; Huguet F; Van Laethem JL; Goldstein D; Glimelius B; Artru P; Borbath I; Bouché O; Shannon J; André T; Mineur L; Chibaudel B; Bonnetain F; Louvet C, 2016, 'Effect of chemoradiotherapy vs chemotherapy on survival in patients with locally advanced pancreatic cancer controlled after 4 months of gemcitabine with or without erlotinib the LAP07 randomized clinical trial', JAMA - Journal of the American Medical Association, 315, pp. 1844 - 1853, http://dx.doi.org/10.1001/jama.2016.4324

He EY; Hawkins NJ; Mak G; Roncolato F; Goldstein D; Liauw W; Clingan P; Chin M; Ward RL, 2016, 'The Impact of Mismatch Repair Status in Colorectal Cancer on the Decision to Treat With Adjuvant Chemotherapy: An Australian Population-Based Multicenter Study', ONCOLOGIST, 21, pp. 618 - 625, http://dx.doi.org/10.1634/theoncologist.2015-0530

Chiorean EG; Von Hoff DD; Reni M; Arena FP; Infante JR; Bathini VG; Wood TE; Mainwaring PN; Muldoon RT; Clingan PR; Kunzmann V; Ramanathan RK; Tabernero J; Goldstein D; McGovern D; Lu B; Ko A, 2016, 'CA19-9 decrease at 8 weeks as a predictor of overall survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic pancreatic cancer', Annals of Oncology, 27, pp. 654 - 660, http://dx.doi.org/10.1093/annonc/mdw006

Ramanathan RK; Goldstein D; Korn RL; Arena F; Moore M; Siena S; Teixeira L; Tabernero J; Van Laethem JL; Liu H; McGovern D; Lu B; Von Hoff DD, 2016, 'Positron emission tomography response evaluation from a randomized phase III trial of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone for patients with metastatic adenocarcinoma of the pancreas', Annals of Oncology, 27, pp. 648 - 653, http://dx.doi.org/10.1093/annonc/mdw020

He EYJ; Hawkins NJ; Mak G; Roncolato F; Goldstein D; Liauw W; Clingan P; Chin M; Ward RL, 2016, 'The impact of mismatch repair status in colorectal cancer on the decision to treat with adjuvant chemotherapy: An Australian population-based multicenter study', Oncologist, 21, pp. 618 - 625, http://dx.doi.org/10.1634/theoncologist.2015-0530

Back to profile page